Agios Pharmaceuticals Inc. (AGIO)
NASDAQ
Closed
Aug 21, 2026
Day's Range
32.9552 wk Range
22.24Overview - AGIO - Agios Pharmaceuticals Inc.
Key Statistics
Valuation
Enterprise Value
1.38B
P/E (Trailing)
‪3.82‬
P/E (Forward)
‪-8.38‬
PEG Ratio
‪-0.30‬
Price / Sales (TTM)
‪20.08‬
Price / Book
‪1.92‬
EV / EBITDA
‪-3.06‬
Profitability
Gross Margin
‪93.30%‬
Profit Margin
‪88.25%‬
Operating Margin
‪-247.07%‬
Return on Assets
‪-22.24%‬
Return on Equity
‪-34.33%‬
Ownership
Shares Outstanding
59.60M
Float
50.01M
Short % of Shares Outstanding
‪11.58%‬
Held by Insiders
‪1.06%‬
Held by Institutions
‪112.34%‬
Price stats
Beta
‪0.58‬
50-Day Avg
‪35.56‬
200-Day Avg
‪30.93‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
10 analysts
Shariah Compliance
Report Date: Feb 20, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - AGIO - Agios Pharmaceuticals Inc.
Peers - AGIO - Agios Pharmaceuticals Inc.
Peer Comparison
Compared with companies in Biotechnology listed on NASDAQ.
- AGIONASDAQAgios Pharmaceuticals Inc.2.09BMarket Cap-8.77%52-week change3.82P/E (Trailing)‪88.25%‬Profit Margin
- ARGXNASDAQargenx SE American Depositary Receipt65.04BMarket Cap+34.86%52-week change39.69P/E (Trailing)‪32.26%‬Profit Margin
- ALNYNASDAQAlnylam Pharmaceuticals Inc31.60BMarket Cap-87.81%52-week change41.15P/E (Trailing)‪16.12%‬Profit Margin
- BNTXNASDAQBioNTech SE29.28BMarket Cap+9.87%52-week change160.80P/E (Trailing)‪-63.63%‬Profit Margin
- ASNDNASDAQAscendis Pharma A/S16.61BMarket Cap+24.84%52-week change19.38P/E (Trailing)‪70.84%‬Profit Margin
- BBIONASDAQBridgeBio Pharma, Inc.15.93BMarket Cap+41.98%52-week change-21.56P/E (Trailing)‪-97.02%‬Profit Margin
- BMRNNASDAQBiomarin Pharmaceutical Inc.12.91BMarket Cap+12.29%52-week change180.16P/E (Trailing)‪2.14%‬Profit Margin
Profile Summary - AGIO - Agios Pharmaceuticals Inc.
About
Agios Pharmaceuticals Inc. is a biopharmaceutical company specializing in cellular metabolism to develop differentiated medicines for rare diseases, with a particular emphasis on classical hematology. The company focuses on creating potentially transformative small-molecule therapies targeting unmet medical needs in…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
